We have demonstrated previously that
D-myo-inositol 4-(hexadecyloxy)-3(S)-methoxybutanephosphonate (C4-PI), an isosteric
phosphonate analog of
phosphatidylinositol developed to inhibit
inositol lipid metabolism, was unable to inhibit
phosphatidylinositol (
PI) 3-kinase activity. We now report the effects of the compound on other aspects of
inositol metabolism. We demonstrated that
C4-PI inhibits the activity of purified recombinant PI-
phospholipase C-beta (
PLC-beta) at all concentrations tested; it enhanced the activity of PI-
PLC-gamma and PI-PLC-delta at low concentrations (10 microM), while severely inhibiting their activities at higher concentrations. In the
breast cancer cell lines MCF-7 (
estrogen receptor positive) and MDA-MB-468 (
estrogen receptor negative),
C4-PI had no effect on the uptake of D-myo-
inositol but severely inhibited its incorporation into PI. In spite of the drastic decrease in PI synthesis,
C4-PI did not affect the levels of
inositol incorporated into
phosphatidylinositol 4,5-bisphosphate (PIP2) in the cells. In vitro assays showed that
C4-PI inhibited PI synthase activity (inhibition of 35% at 50 microM) but had little effect on
PI 4-kinase activity (inhibition of 13% at 150 microM).
C4-PI inhibited the proliferation of MCF-7 and MDA-MB-468 cell lines with IC(50) values of 12 and 18 microM. Taken together, the results suggest that the accumulation of [3H]
inositol in PIP2 in cells incubated with
C4-PI may be due to the inhibition of PIP2 hydrolysis in the cells with no effect on its synthesis. The role of these C4-PI-induced effects in the mechanism of growth inhibition by
C4-PI remains to be established.